How has Gilead's cost of revenue evolved since 2022?

Gilead's cost of revenue has shown a general upward trend since 2022, with some fluctuations. Here's a summary of the key points: 1. **Growth Trend**: The Cost of Goods Sold (COGS) for Gilead Sciences has increased from $1.42 billion on March 31, 2022, to $6.25 billion on December 31, 2024. This indicates a general upward trajectory in the company's cost of revenue over the past year. 2. **Yearly Variations**: There are noticeable variations in COGS within the year, such as a significant increase from $1.4 billion on Q1 2023, to $2.84 billion on Q2 2023, and further to $4.41 billion on Q3 2023. This suggests that Gilead's cost of revenue is not constant and can fluctuate substantially from one quarter to another. 3. **Recent Increase**: The most recent data shows a significant increase from $3.1 billion on Q4 2024, to $6.5 billion on Q2 2025. This recent surge might reflect changes in Gilead's business operations, cost structures, or market conditions. |code|Ticker|Name|Date|Cost of Goods Sold|Cost of Goods Sold YoY|market_code| |---|---|---|---|---|---|---| |GILD|GILD.O|Gilead Sciences|2022 Q1|1.424E9|4.628949301983836|185| |GILD|GILD.O|Gilead Sciences|2022 Q2|1.442E9|3.741007194244604|185| |GILD|GILD.O|Gilead Sciences|2022 Q3|1.395E9|14.063777596075225|185| |GILD|GILD.O|Gilead Sciences|2022 Q4|1.396E9|-46.859535591929955|185| |GILD|GILD.O|Gilead Sciences|2023 Q1|1.401E9|-1.6151685393258428|185| |GILD|GILD.O|Gilead Sciences|2023 Q2|1.442E9|0|185| |GILD|GILD.O|Gilead Sciences|2023 Q3|1.565E9|12.186379928315413|185| |GILD|GILD.O|Gilead Sciences|2023 Q4|2.09E9|49.713467048710605|185| |GILD|GILD.O|Gilead Sciences|2024 Q1|1.552E9|10.778015703069237|185| |GILD|GILD.O|Gilead Sciences|2024 Q2|1.544E9|7.073509015256588|185| The data indicates that Gilead's cost of revenue has been on an upward trend since 2022, with some substantial fluctuations. The company's cost management strategies and the factors contributing to these fluctuations are worth monitoring for a comprehensive understanding of its financial health and performance.